Conceptually, TGF-β signaling has long been recognized as an attractive therapeutic target for intervention in cancer and fibrosis, including liver [51], pulmonary [52,55,73,75,76], and kidney fibrosis [53,57,77]. Here, TGFB1 is linked to cancer.